Limits...
Newly synthesized anticancer drug HUHS1015 is effective on malignant pleural mesothelioma.

Kaku Y, Nagaya H, Tsuchiya A, Kanno T, Gotoh A, Tanaka A, Shimizu T, Nakao S, Tabata C, Nakano T, Nishizaki T - Cancer Sci. (2014)

Bottom Line: The newly synthesized naftopidil analogue HUHS1015 reduced cell viability in malignant pleural mesothelioma cell lines MSTO-211H, NCI-H28, NCI-H2052, and NCI-H2452, with the potential greater than that for the anticancer drugs paclitaxel or cisplatin at concentrations higher than 30 μM.HUHS1015 induced both necrosis and apoptosis of MSTO-211H and NCI-H2052 cells.HUHS1015 upregulated expression of mRNAs for Puma, Hrk, and Noxa in MSTO-211H and NCI-H2052 cells, suggesting HUHS1015-induced mitochondrial apoptosis.

View Article: PubMed Central - PubMed

Affiliation: Division of Bioinformation, Department of Physiology, Hyogo College of Medicine, Nishinomiya, Japan.

Show MeSH

Related in: MedlinePlus

Suppression of NCI-H2052 tumor growth in mice induced by HUHS1015. NCI-H2052 cells were inoculated s.c. into the flank of mice, and a week later a physiological salt solution (Control) or HUHS1015 (9.15 mg/kg) was injected i.p. twice a week. (a) Tumor volume (mean ± SEM) (n = 6 independent mice). (b) Survival rate (the mean ± SEM) (n = 6 independent mice). (c) Body weight (mean ± SEM) (n = 6 independent mice).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4317914&req=5

fig07: Suppression of NCI-H2052 tumor growth in mice induced by HUHS1015. NCI-H2052 cells were inoculated s.c. into the flank of mice, and a week later a physiological salt solution (Control) or HUHS1015 (9.15 mg/kg) was injected i.p. twice a week. (a) Tumor volume (mean ± SEM) (n = 6 independent mice). (b) Survival rate (the mean ± SEM) (n = 6 independent mice). (c) Body weight (mean ± SEM) (n = 6 independent mice).

Mentions: We finally examined the effect of HUHS1015 on NCI-H2052 cell proliferation using mice inoculated with NCI-H2052 cells. Intraperitoneal injection with HUHS1015 at a dose of 9.15 mg/kg, corresponding to approximately 25 μM, twice a week significantly inhibited NCI-H2052 cell growth compared with that for control mice without HUHS1015 (P < 0.001, Fisher's protected least significant difference test) (Fig. 7a). All the mice treated with HUHS1015 survived 8 weeks after the beginning of HUHS1015 injection (Fig. 7b) and HUHS1015 had no effect on body weight (Fig. 7c). In addition, we have not confirmed apparent side-effects of HUHS1015 throughout these experiments. These results indicate that HUHS1015 could exert its beneficial anticancer effect on malignant pleural mesothelioma.


Newly synthesized anticancer drug HUHS1015 is effective on malignant pleural mesothelioma.

Kaku Y, Nagaya H, Tsuchiya A, Kanno T, Gotoh A, Tanaka A, Shimizu T, Nakao S, Tabata C, Nakano T, Nishizaki T - Cancer Sci. (2014)

Suppression of NCI-H2052 tumor growth in mice induced by HUHS1015. NCI-H2052 cells were inoculated s.c. into the flank of mice, and a week later a physiological salt solution (Control) or HUHS1015 (9.15 mg/kg) was injected i.p. twice a week. (a) Tumor volume (mean ± SEM) (n = 6 independent mice). (b) Survival rate (the mean ± SEM) (n = 6 independent mice). (c) Body weight (mean ± SEM) (n = 6 independent mice).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4317914&req=5

fig07: Suppression of NCI-H2052 tumor growth in mice induced by HUHS1015. NCI-H2052 cells were inoculated s.c. into the flank of mice, and a week later a physiological salt solution (Control) or HUHS1015 (9.15 mg/kg) was injected i.p. twice a week. (a) Tumor volume (mean ± SEM) (n = 6 independent mice). (b) Survival rate (the mean ± SEM) (n = 6 independent mice). (c) Body weight (mean ± SEM) (n = 6 independent mice).
Mentions: We finally examined the effect of HUHS1015 on NCI-H2052 cell proliferation using mice inoculated with NCI-H2052 cells. Intraperitoneal injection with HUHS1015 at a dose of 9.15 mg/kg, corresponding to approximately 25 μM, twice a week significantly inhibited NCI-H2052 cell growth compared with that for control mice without HUHS1015 (P < 0.001, Fisher's protected least significant difference test) (Fig. 7a). All the mice treated with HUHS1015 survived 8 weeks after the beginning of HUHS1015 injection (Fig. 7b) and HUHS1015 had no effect on body weight (Fig. 7c). In addition, we have not confirmed apparent side-effects of HUHS1015 throughout these experiments. These results indicate that HUHS1015 could exert its beneficial anticancer effect on malignant pleural mesothelioma.

Bottom Line: The newly synthesized naftopidil analogue HUHS1015 reduced cell viability in malignant pleural mesothelioma cell lines MSTO-211H, NCI-H28, NCI-H2052, and NCI-H2452, with the potential greater than that for the anticancer drugs paclitaxel or cisplatin at concentrations higher than 30 μM.HUHS1015 induced both necrosis and apoptosis of MSTO-211H and NCI-H2052 cells.HUHS1015 upregulated expression of mRNAs for Puma, Hrk, and Noxa in MSTO-211H and NCI-H2052 cells, suggesting HUHS1015-induced mitochondrial apoptosis.

View Article: PubMed Central - PubMed

Affiliation: Division of Bioinformation, Department of Physiology, Hyogo College of Medicine, Nishinomiya, Japan.

Show MeSH
Related in: MedlinePlus